Management of bleeding associated with dabigatran and rivaroxaban: A survey of current practices

Lisa M. Baumann Kreuziger; Mark T Reding

doi:10.1016/j.thromres.2013.07.011

Management of bleeding associated with dabigatran and rivaroxaban: A survey of current practices

Lisa M. Baumann Kreuziger, Mark T Reding

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	e161-e163
Journal	Thrombosis Research
Volume	132
Issue number	2
DOIs	https://doi.org/10.1016/j.thromres.2013.07.011
State	Published - Aug 2013

Bibliographical note

Funding Information:
We acknowledge NIH T32 Training grant 5T32HL00706 for funding LBK’s time to complete this project. The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

Funding Information:
A NIH T32 training grant supported LBK’s fellowship. MTR served as consultant, speaker, advisory board member, and has received research funding from Novo Nordisk, Baxter, Bayer, Biogen Idec, Octapharma, and Pfizer.

Access

10.1016/j.thromres.2013.07.011

OpenUrl availability

Full text

Cite this

@article{88fb8791ea604d9ebdd3605c1b33b11f,

title = "Management of bleeding associated with dabigatran and rivaroxaban: A survey of current practices",

author = "{Baumann Kreuziger}, {Lisa M.} and Reding, {Mark T}",

note = "Funding Information: We acknowledge NIH T32 Training grant 5T32HL00706 for funding LBK{\textquoteright}s time to complete this project. The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. Funding Information: A NIH T32 training grant supported LBK{\textquoteright}s fellowship. MTR served as consultant, speaker, advisory board member, and has received research funding from Novo Nordisk, Baxter, Bayer, Biogen Idec, Octapharma, and Pfizer. ",

year = "2013",

month = aug,

doi = "10.1016/j.thromres.2013.07.011",

language = "English (US)",

volume = "132",

pages = "e161--e163",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Management of bleeding associated with dabigatran and rivaroxaban

T2 - A survey of current practices

AU - Baumann Kreuziger, Lisa M.

AU - Reding, Mark T

N1 - Funding Information: We acknowledge NIH T32 Training grant 5T32HL00706 for funding LBK’s time to complete this project. The funding source had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication. Funding Information: A NIH T32 training grant supported LBK’s fellowship. MTR served as consultant, speaker, advisory board member, and has received research funding from Novo Nordisk, Baxter, Bayer, Biogen Idec, Octapharma, and Pfizer.

PY - 2013/8

Y1 - 2013/8

UR - http://www.scopus.com/inward/record.url?scp=84883749228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883749228&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2013.07.011

DO - 10.1016/j.thromres.2013.07.011

M3 - Article

C2 - 23916381

AN - SCOPUS:84883749228

SN - 0049-3848

VL - 132

SP - e161-e163

JO - Thrombosis Research

JF - Thrombosis Research

IS - 2

ER -

Management of bleeding associated with dabigatran and rivaroxaban: A survey of current practices

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this